Evidence map›Paper›PMID 41529072›Full record

ArticlePLoS computational biology2026

Exosome-mediated chemotaxis optimizes leader-follower cell migration.

Louis González, Andrew Mugler

Abstract read
In one paragraph

Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Louis GonzálezDepartment of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Andrew MuglerDepartment of Physics and Astronomy, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.ORCID https://orcid.org/0000-0001-9367-7026

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cells frequently employ extracellular vesicles, or exosomes, to signal across long distances and coordinate collective actions. Exosomes diffuse slowly, can be actively degraded, and contain stochastic amounts of molecular cargo. These features raise the question of the efficacy of exosomes as a directional signal, but this question has not be systematically investigated. We develop a theoretical and computational approach to quantify the limits of exosome-mediated chemotaxis at the individual cell level. In our model, a leader cell secretes exosomes, which diffuse in the extracellular space, and a follower cell guides its migration by integrating discrete exosome detections over a finite memory window. We combine analytical calculations and stochastic simulations and show that the chemotactic velocity exhibits a non-monotonic dependence on the exosome cargo size. Small exosomes produce frequent but weak signals, whereas large exosomes produce strong but infrequent encounters. In the presence of nonlinear signal transduction, this tradeoff leads to an optimal cargo size that maximizes information throughput, as quantified by the average speed of the follower cell. Using a reduced one-dimensional model, we derive closed-form expressions coupling the optimal cargo size to follower speed as a function of secretion rate, memory time, and detection sensitivity. These results identify molecular packaging and memory integration as key determinants of exosome-mediated information transmission and highlight general design principles for optimization of migration under guidance by discrete and diffusible signaling particles.

Indexed as

Cell MovementChemotaxisExosomesModels, BiologicalAnimalsComputational BiologyComputer SimulationSignal TransductionStochastic Processes

Identifiers

PMID41529072
PMCPMC12826496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.